
Drugs IPOs Depend o...


| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 2.07B | 1.96B | 1.97B | 1.94B |
| Cost of Sales | 0.00 | 0.00 | 0.00 | n.a. |
| Gross Operating Profit | 619.23M | 541.77M | 465.08M | 534.03M |
| Selling, General, and Administrative Expenses | n.a. | n.a. | n.a. | n.a. |
| Research & Development | n.a. | n.a. | n.a. | n.a. |
| Operating Income before D & A (EBITDA) | 619.23M | 541.77M | 465.08M | 534.03M |
| Depreciation & Amortization | n.a. | n.a. | n.a. | n.a. |
| Interest Income | n.a. | n.a. | n.a. | n.a. |
| Other Income - Net | n.a. | n.a. | n.a. | n.a. |
| Special Income / Charges | 150.53M | 12.19M | -13.94M | 13.43M |
| Total Income Before Interest Expenses (EBIT) | 769.76M | 553.96M | 451.14M | 547.46M |
| Interest Expense | 457.67M | 469.24M | 470.65M | 516.62M |
| Pre-Tax Income | 312.09M | 84.73M | -19.51M | 30.84M |
| Income Taxes | 539.00K | 728.00K | 334.00K | 2.81M |
| Minority Interest | 39.48M | 41.61M | 12.37M | 19.76M |
| Net Income From Continuing Operations | 311.56M | 84.00M | -19.84M | 28.03M |
| Net Income From Discontinued Operations | 569.65M | 851.20M | 315.83M | 354.00M |
| Net Income From Total Operations | 881.20M | 935.20M | 295.98M | 382.03M |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | 841.72M | 893.58M | 283.61M | 362.27M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
161.02M | 71.80M | -5.90M | 14.60M |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | 301.20M | 70.13M | -34.21M | 13.55M |
| Basic EPS from Continuing Ops. | 0.93 | 0.23 | -0.11 | 0.05 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | 0.93 | 0.23 | -0.11 | 0.05 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 1.80 | 2.75 | 1.06 | 1.22 |
| Basic EPS, Total | 2.73 | 2.98 | 0.95 | 1.27 |
| Basic Normalized Net Income/Share | 0.48 | 0.20 | -0.03 | 0.03 |
| EPS fr Continuing Ops. | 0.92 | 0.22 | -0.11 | 0.05 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | 0.92 | 0.22 | -0.11 | 0.05 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 1.78 | 2.73 | 1.06 | 1.22 |
| EPS, Total | 2.70 | 2.95 | 0.95 | 1.27 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.48 | 0.19 | -0.03 | 0.03 |
| Dividends Paid per Share | 1.78 | 1.58 | 1.47 | 1.64 |